AC Immune’s (ACIU) Buy Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of AC Immune (NASDAQ:ACIU) in a research note issued to investors on Tuesday,Benzinga reports. BTIG Research currently has a $8.00 price objective on the stock.

ACIU has been the topic of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of AC Immune in a report on Wednesday, October 8th. Zacks Research raised AC Immune from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 9th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, AC Immune currently has an average rating of “Hold” and an average target price of $10.00.

AC Immune Stock Performance

Shares of ACIU opened at $3.45 on Tuesday. The firm has a market cap of $346.41 million, a PE ratio of -5.95 and a beta of 1.58. AC Immune has a 52-week low of $1.43 and a 52-week high of $4.00. The business’s 50 day moving average price is $2.91 and its two-hundred day moving average price is $2.28.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02. AC Immune had a negative net margin of 174.94% and a negative return on equity of 49.35%. The company had revenue of $0.95 million during the quarter, compared to the consensus estimate of $0.81 million. Research analysts predict that AC Immune will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. BVF Inc. IL grew its holdings in AC Immune by 1.5% during the first quarter. BVF Inc. IL now owns 19,822,436 shares of the company’s stock worth $37,068,000 after buying an additional 300,000 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after acquiring an additional 172,796 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of AC Immune in the third quarter valued at about $549,000. Banque Cantonale Vaudoise bought a new position in shares of AC Immune during the first quarter valued at about $50,000. Finally, Sei Investments Co. purchased a new position in AC Immune during the second quarter worth about $51,000. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.